Disc Medicine logo

Disc Medicine

IRON | NASDAQ
Chart Builder DCF Calculator
$76.59
-$3.41 (-4.26%)
At close: Nov 16, 2026, 4:00 PM ET
$76.59
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.26%

Rating

Updated: Nov 16, 2026
20.3
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #989/1021 (Top 97%)

Key Statistics

Market Data

Market Cap $2.94B
1D Range
76.40 80.37
52W Range
55.74 94.11

Valuation (TTM)

PE -12.04
PB 4.87
EV/EBITDA -9.74

Valuation (NTM)

Forward PE N/A
Forward PEG 9.25
Price Target $120.00
Loading financial charts...

Profile

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeu...

Sector Healthcare
Industry Biotechnology
Employees 165
IPO Date Aug 12, 2020
Fiscal Year January - December

Latest News

12 days ago · globenewswire.com

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Disc Medicine to Participate in Upcoming Investor Conferences

15 days ago · globenewswire.com

Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

27 days ago · globenewswire.com

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

28 days ago · globenewswire.com

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript

28 days ago · seekingalpha.com

Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study

29 days ago · benzinga.com

Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine stock soars: take profit or buy into strength?

29 days ago · invezz.com

Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment

29 days ago · gurufocus.com

Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission

29 days ago · marketbeat.com

Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

29 days ago · barrons.com

Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes

Earnings

Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$120.00
Upside
+56.68%
Buy (8)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.